IN8bio (INAB) Competitors

$0.31

-0.01 (-2.12%)

(As of 05:39 PM ET)

INAB vs. HCWB, ORPH, ENLV, TTOO, LVTX, VHAQ, THTX, CLDI, EGRX, and ANEB

Should you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include HCW Biologics (HCWB), Orphazyme A/S (ORPH), Enlivex Therapeutics (ENLV), T2 Biosystems (TTOO), LAVA Therapeutics (LVTX), Viveon Health Acquisition (VHAQ), Theratechnologies (THTX), Calidi Biotherapeutics (CLDI), Eagle Pharmaceuticals (EGRX), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "medical" sector.

IN8bio vs.

HCW Biologics (NASDAQ:HCWB) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, community ranking, profitability, earnings, dividends and risk.

: IN8bio received 16 more outperform votes than HCW Biologics when rated by MarketBeat users. However, 100.00% of users gave HCW Biologics an outperform vote while only 70.97% of users gave IN8bio an outperform vote.
Company Underperform Outperform
HCW Biologics Outperform Votes
6
100.00%
Underperform Votes
No Votes
IN8bio Outperform Votes
22
70.97%
Underperform Votes
9
29.03%
: IN8bio has a net margin of 0.00% compared to HCW Biologics' net margin of -978.03%. IN8bio's return on equity of -173.12% beat HCW Biologics' return on equity.
Company Net Margins Return on Equity Return on Assets
HCW Biologics -978.03% -385.90% -126.44%
IN8bio N/A -173.12% -118.40%
: HCW Biologics has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500.
: IN8bio has a consensus target price of $10.00, suggesting a potential upside of 3,014.29%. Given IN8bio's higher possible upside, analysts plainly believe IN8bio is more favorable than HCW Biologics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HCW Biologics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
IN8bio
0 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
3.00
: In the previous week, HCW Biologics' average media sentiment score of 1.00 equaled IN8bio'saverage media sentiment score.
Company Overall Sentiment
HCW Biologics Positive
IN8bio Positive
: 3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 49.9% of HCW Biologics shares are held by company insiders. Comparatively, 15.5% of IN8bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: HCW Biologics has higher revenue and earnings than IN8bio. HCW Biologics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
HCW Biologics $3.92M 4.86 -$24.99M -$0.76 -0.66
IN8bio N/A N/A -$30.01M -$0.91 -0.35

Company	Underperform	Outperform
HCW Biologics	Outperform Votes 6 100.00%	Underperform Votes No Votes
IN8bio	Outperform Votes 22 70.97%	Underperform Votes 9 29.03%

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-978.03%	-385.90%	-126.44%
IN8bio	N/A	-173.12%	-118.40%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
IN8bio	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Company	Overall Sentiment
HCW Biologics	Positive
IN8bio	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$3.92M	4.86	-$24.99M	-$0.76	-0.66
IN8bio	N/A	N/A	-$30.01M	-$0.91	-0.35

Summary

IN8bio beats HCW Biologics on 8 of the 14 factors compared between the two stocks.

Ad Behind the Markets

“Buffett Indicator” Predicts 62% Stock Market Crash

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>

Get IN8bio News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INAB vs. The Competition

Export to Excel

Metric	IN8bio	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.17M	$3.08B	$5.52B	$8.44B
Dividend Yield	N/A	1.95%	4.96%	4.06%
P/E Ratio	-0.35	28.62	147.34	18.92
Price / Sales	N/A	269.08	1,687.21	84.33
Price / Cash	N/A	148.44	37.15	31.48
Price / Book	0.55	3.98	4.94	4.56
Net Income	-$30.01M	-$43.91M	$114.92M	$225.32M
7 Day Performance	1.45%	-0.25%	9.02%	4.19%
1 Month Performance	-39.13%	24.64%	15.50%	7.96%
1 Year Performance	-72.32%	18.99%	33.12%	15.09%

IN8bio Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCWB HCW Biologics	0.8051 of 5 stars 0.81 / 5 stars	$0.50 -16.6%	N/A	-76.4%	$19.05M	$3.92M	-0.66	40	Gap Up High Trading Volume
ORPH Orphazyme A/S	0 of 5 stars 0.00 / 5 stars	N/A	N/A	N/A	$30.72M	N/A	0.00	141
ENLV Enlivex Therapeutics	3.3218 of 5 stars 3.32 / 5 stars	$1.50 -3.2%	$6.00 +300.0%	-18.5%	$31.31M	N/A	-1.08	70	Gap Up High Trading Volume
TTOO T2 Biosystems	2.2213 of 5 stars 2.22 / 5 stars	$2.20 +2.3%	$5.00 +127.3%	-93.5%	$38.46M	$7.19M	0.00	180	News Coverage
LVTX LAVA Therapeutics	2.4546 of 5 stars 2.45 / 5 stars	$1.66 -1.2%	$6.00 +261.4%	-1.2%	$42.08M	$7.40M	-1.54	60	Gap Down
VHAQ Viveon Health Acquisition	0 of 5 stars 0.00 / 5 stars	$10.00 flat	N/A	N/A	$56.60M	N/A	0.00	2	High Trading Volume
THTX Theratechnologies	0 of 5 stars 0.00 / 5 stars	$1.22 +1.7%	N/A	-43.5%	$56.10M	$81.76M	-6.42	140	Upcoming Earnings
CLDI Calidi Biotherapeutics	1.9071 of 5 stars 1.91 / 5 stars	$1.10 -0.9%	$16.67 +1,415.2%	N/A	$56.02M	$50,000.00	0.00	38	Gap Down
EGRX Eagle Pharmaceuticals	4.0617 of 5 stars 4.06 / 5 stars	$4.27 -0.2%	N/A	-72.2%	$55.45M	$257.55M	3.62	100	Upcoming Earnings Analyst Forecast
ANEB Anebulo Pharmaceuticals	2.8019 of 5 stars 2.80 / 5 stars	$2.08 +4.0%	$6.67 +220.5%	-36.4%	$53.94M	N/A	-5.62	4	Positive News